Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 09-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -246,290 | -116,484 | -123,096 | N/A | 78,500 |
| Depreciation Amortization | 2,188 | 1,646 | 740 | N/A | 63,800 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | -300 |
| Accounts receivable | N/A | 192 | 895 | N/A | -56,100 |
| Accounts payable and accrued liabilities | 1,921 | -3,425 | -858 | N/A | 14,700 |
| Other Working Capital | 12,362 | -7,694 | 481 | N/A | -25,200 |
| Other Operating Activity | 61,090 | 4,184 | 476 | 0 | 61,200 |
| Operating Cash Flow | $-168,729 | $-121,581 | $-121,362 | $N/A | $136,600 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -801 | -358 | -944 | N/A | -28,100 |
| Net Acquisitions | N/A | N/A | N/A | N/A | 7,300 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -217,200 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 68,500 |
| Purchase Sale Intangibles | -2,008 | -1,790 | -1,526 | N/A | N/A |
| Other Investing Activity | -2,027 | -1,890 | -1,562 | 0 | 17,000 |
| Investing Cash Flow | $-2,828 | $-2,248 | $-2,506 | $N/A | $-152,500 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 62,898 | N/A | N/A | N/A | N/A |
| Debt Repayment | N/A | N/A | N/A | N/A | -700 |
| Common Stock Issued | 433,212 | 101,655 | -24 | N/A | N/A |
| Common Stock Repurchased | N/A | -141 | N/A | N/A | N/A |
| Other Financing Activity | -1,144 | -1,002 | 0 | 0 | -1,600 |
| Financing Cash Flow | $494,966 | $100,512 | $-24 | $N/A | $-2,300 |
| Exchange Rate Effect | 235 | 61 | -53 | N/A | 800 |
| Beginning Cash Position | 115,551 | 138,807 | 262,752 | N/A | 535,500 |
| End Cash Position | 439,195 | 115,551 | 138,807 | N/A | 518,100 |
| Net Cash Flow | $323,644 | $-23,256 | $-123,945 | $N/A | $-17,400 |
| Free Cash Flow | |||||
| Operating Cash Flow | -168,729 | -121,581 | -121,362 | N/A | 136,600 |
| Capital Expenditure | -801 | -358 | -944 | N/A | -29,400 |
| Free Cash Flow | -169,530 | -121,939 | -122,306 | 0 | 107,200 |